Structure and Function of CB2 Cannabinoid Receptor
CB2 大麻素受体的结构和功能
基本信息
- 批准号:7222011
- 负责人:
- 金额:$ 24.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-09-30 至 2009-04-30
- 项目状态:已结题
- 来源:
- 关键词:Absence of pain sensationAdverse effectsAffinityAffinity ChromatographyAgonistAgreementAmino AcidsAnalgesicsArtsAutoimmune DiseasesBindingBiochemicalBiogenic Amine ReceptorsCNR2 geneCannabinoidsCellular biologyCharacteristicsChemicalsClassCloningCollaborationsConditionConserved SequenceCysteineDecompression SicknessDevelopmentDisulfide LinkageDisulfidesDopamine D2 ReceptorEnsureEthersEthyl EtherExhibitsFamilyFingerprintFluorescence SpectroscopyFutureG-Protein-Coupled ReceptorsGlaucomaGoalsGrowthHelix (Snails)Hydrogen BondingHydroxyl RadicalImmuneImmune systemImmunologic ReceptorsInflammationIonsLigand BindingLigandsLiquid ChromatographyMapsMarijuanaMass Spectrum AnalysisMedicalMetalsMethodologyMethodsModelingModificationMolecularMolecular BiologyMolecular ConformationMutagenesisMutationNatureNeuraxisNuclear Magnetic ResonanceNumbersPeptide FragmentsPeptidesPeripheralPharmaceutical PreparationsPharmacologyPichiaPositioning AttributePost-Translational Protein ProcessingProceduresProcessProductionProlinePropertyProtein ChemistryProtein OverexpressionProteinsProteomicsPurposeReceptor ActivationResearch DesignResearch PersonnelResearch ProposalsResolutionRhodopsinRunningSiteSourceSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationStructureSurfaceSystemTestingTherapeuticTherapeutic AgentsTimeTissuesTransmembrane DomainWorkX-Ray CrystallographyYeastsbasecannabinoid receptordesigndisulfide bondear heliximprovedinsightmimeticsmolecular modelingnovelprogramsprotein aminoacid sequenceprotein structurereceptorreceptor structure functionscale uptool
项目摘要
DESCRIPTION (provided by applicant): The long-term goal of this research proposal is to identify the molecular basis underlying the functions of the CB2 cannabinoid receptor. To achieve this purpose, the following steps will be taken. In Aim 1 and 2, the interactive mutagenesis, molecular modeling and new compound testing studies will be carried out. This combined approach has advanced our understanding, and should continue to reveal new insights on how cannabinoid ligands are recognized by their receptors, the origin of receptor subtype-selectivity, and how these receptors are activated/inactivated. Cannabinoid receptors share many of the conserved sequence motifs seen in other well-studied G protein-coupled receptors (GPCRs), such as rhodopsin and biogenic amine receptors. However, several helix-bending residues and motifs, and a key disulfide bridge present in many other GPCRs are missing in cannabinoid receptors. In Aim 3, Ligand binding crevice exposure of two transmembrane domains of CB2 cannabinoid receptor will be mapped using substituted-cysteine accessibility method. This approach should elucidate structural and functional consequences of the sequence divergence in these trasmembrane domains of cannabinoid receptors.
In Aim 4, Disulfide bond formation of CB2 receptor will be determined directly by the state-of-art methodologies of mass spectrometry. Investigating the unique disulfide bond or absence of a disulfide bond should provide important helix folding information of CB2 receptor, and this will have important implications regarding ligand binding crevice and activation mechanisms of this receptor. Finally, in Aim 5, effort will be devoted to over-express and purify large amounts of functional CB2 receptor. This challenging task, if successfully completed, should have a significant impact by providing the badly needed pure receptor proteins for future high-resolution biophysical studies. Overall, This study should help us to understand in more molecular detail the structure and function of CB2 receptor. CB2 is primarily distributed in the immune system. It is very important for the immune-modulatory effects of marijuana. In the long run, this study should also help us to develop better cannabinoid mimetics for the treatment of immune system illnesses, such as inflammation and autoimmune diseases. The drugs that specifically targeted at CB2 should be devoid of psvchoactive side effects of marijuana.
描述(由申请人提供):这项研究提案的长期目标是确定CB2大麻素受体功能的分子基础。为达到这一目的,将采取以下步骤。在目标1和目标2中,将进行交互诱变、分子模拟和新化合物测试研究。这一结合的方法促进了我们的理解,并应继续揭示大麻素配体如何被其受体识别、受体亚型选择性的起源以及这些受体如何激活/失活的新见解。大麻素受体具有许多与其他研究良好的G蛋白偶联受体(GPCRs)相同的保守序列基序,如视紫红质和生物胺受体。然而,许多其他GPCR中存在的几个螺旋弯曲残基和基序以及一个关键的二硫键桥在大麻素受体中缺失。在目标3中,将使用取代半胱氨酸可及性方法绘制CB2大麻受体两个跨膜结构域的配体结合缝隙暴露图。这一方法应该阐明大麻素受体跨膜区域序列分歧的结构和功能后果。
在目标4中,CB2受体的二硫键形成将直接用最先进的质谱学方法测定。研究CB2受体中独特的二硫键或缺失二硫键将为CB2受体提供重要的螺旋折叠信息,这将对该受体的配体结合缝隙和激活机制具有重要的意义。最后,在目标5中,将致力于过表达和纯化大量有功能的CB2受体。这项具有挑战性的任务如果成功完成,将为未来的高分辨率生物物理研究提供急需的纯受体蛋白,从而产生重大影响。总体而言,这项研究应该有助于我们更详细地了解CB2受体的结构和功能。CB2主要分布在免疫系统中。这对大麻的免疫调节作用非常重要。从长远来看,这项研究还应该帮助我们开发更好的大麻素模拟物,用于治疗免疫系统疾病,如炎症和自身免疫性疾病。针对CB2的药物应该没有大麻的副作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ZHAO-HUI SONG其他文献
ZHAO-HUI SONG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ZHAO-HUI SONG', 18)}}的其他基金
Endocannabinoid system as a therapeutic target for PVR
内源性大麻素系统作为 PVR 的治疗靶点
- 批准号:
10747004 - 财政年份:2023
- 资助金额:
$ 24.39万 - 项目类别:
Cannabinoid Receptors and Novel Antiglaucoma Drugs
大麻素受体和新型抗青光眼药物
- 批准号:
7655084 - 财政年份:2003
- 资助金额:
$ 24.39万 - 项目类别:
Cannabinoid Receptors and Novel Antiglaucoma Drugs
大麻素受体和新型抗青光眼药物
- 批准号:
6774098 - 财政年份:2003
- 资助金额:
$ 24.39万 - 项目类别:
Cannabinoid Receptors and Novel Antiglaucoma Drugs
大麻素受体和新型抗青光眼药物
- 批准号:
7895529 - 财政年份:2003
- 资助金额:
$ 24.39万 - 项目类别:
Cannabinoid Receptors and Novel Antiglaucoma Drugs
大麻素受体和新型抗青光眼药物
- 批准号:
6923583 - 财政年份:2003
- 资助金额:
$ 24.39万 - 项目类别:
Cannabinoid Receptors and Novel Antiglaucoma Drugs
大麻素受体和新型抗青光眼药物
- 批准号:
6681560 - 财政年份:2003
- 资助金额:
$ 24.39万 - 项目类别:
Cannabinoid Receptors and Novel Antiglaucoma Drugs
大麻素受体和新型抗青光眼药物
- 批准号:
7095301 - 财政年份:2003
- 资助金额:
$ 24.39万 - 项目类别:
Structure and Function of CB2 Cannabinoid Receptor
CB2 大麻素受体的结构和功能
- 批准号:
7061327 - 财政年份:1998
- 资助金额:
$ 24.39万 - 项目类别:
Structure and Function of CB2 Cannabinoid Receptor
CB2 大麻素受体的结构和功能
- 批准号:
6886758 - 财政年份:1998
- 资助金额:
$ 24.39万 - 项目类别:
Structure and Function of CB2 Cannabinoid Receptor
CB2 大麻素受体的结构和功能
- 批准号:
7440803 - 财政年份:1998
- 资助金额:
$ 24.39万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 24.39万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 24.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 24.39万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 24.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 24.39万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 24.39万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 24.39万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 24.39万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 24.39万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 24.39万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




